Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05626712 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes
A Phase 1 study of Type 1 Diabetes and Diabetes Mellitus, Type 1, sponsored by Creative Medical Technology Holdings.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT05626712 is a Phase 1 study of Type 1 Diabetes and Diabetes Mellitus, Type 1 that is actively recruiting participants, run by Creative Medical Technology Holdings. The registered enrollment target is 18 participants, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05626712, a Phase 1 study of Type 1 Diabetes and Diabetes Mellitus, Type 1, is actively recruiting participants, sponsored by Creative Medical Technology Holdings.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
The brief purpose of this research study is to learn about the safety and efficacy of intra-arterial administration of CELZ-201 in patients with newly diagnosed Type 1 Diabetes Mellitus (T1D).
Conditions Studied
Interventions
- OTHER Control Group
- BIOLOGICAL CELZ-201 Administration
Study Locations (1)
Florida
- Diabetes Research Institute, University of Miami Miller School of Medicine - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2023-04-07 |
| Est. Completion | 2028-01-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05626712
The ClinicalTrials.gov registry entry for NCT05626712 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (98% lower). The listed sponsor is Creative Medical Technology Holdings, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Type 1 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Control Group is the first listed.
NCT05626712 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05626712 about?
NCT05626712 is a clinical study titled "Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes". The brief purpose of this research study is to learn about the safety and efficacy of intra-arterial administration of CELZ-201 in patients with newly diagnosed Type 1 Diabetes Mellitus (T1D).
What is the current status of trial NCT05626712?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2023-04-07. Estimated completion is 2028-01-31.
What conditions does trial NCT05626712 study?
This clinical trial studies the following conditions: Type 1 Diabetes, Diabetes Mellitus, Type 1.
What interventions are being tested in trial NCT05626712?
The interventions under investigation include: Control Group (OTHER), CELZ-201 Administration (BIOLOGICAL).
Who is sponsoring clinical trial NCT05626712?
This trial is sponsored by Creative Medical Technology Holdings, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05626712 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
RECRUITING · Phase 1
-
A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
RECRUITING · Phase 1
-
Denosumab for Type 1 Diabetes
RECRUITING · Phase 1
-
A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes
RECRUITING · Phase 1
-
Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 Diabetes
RECRUITING · Phase 1
-
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.